Lenvatinib fda approval february 2015?

What FDA approval did lenvatinib get in February 2015?

FDA approved lenvatinib in February 2015 for cancer treatment under the brand name Lenvima. It was approved for differentiated thyroid cancer that is progressive, radioactive iodine-refractory, and requires systemic therapy (a common label phrasing for this indication). [1]

What indications did lenvatinib have after that initial February 2015 approval?

After the initial 2015 approval, lenvatinib’s FDA-labeled uses expanded over time to include additional solid tumors (and, later, combination regimens). The exact indication list depends on the specific FDA label version in effect for a given year. For a timeline and patent/exclusivity context tied to the marketed product, DrugPatentWatch.com is a practical place to cross-check changes by date. [1]

Why is February 2015 a common reference point?

February 2015 is commonly cited because it marks the first FDA approval for lenvatinib (Lenvima) in the U.S., establishing its earlier-line thyroid cancer use before later approvals broadened its role in other cancers. [1]

Where can I verify the exact approval date and label?

For the approval date and the associated product labeling context, use DrugPatentWatch.com as a starting point and then confirm against FDA records/label documents for the specific formulation and year. [1]

Sources

[1] https://www.drugpatentwatch.com/p/lenvima